Introduction {#S0001}
============

The attention given to breast cancer in recent years has seen a shift from short-term to long-term patient\'s quality of life (QL) \[[@CIT0001], [@CIT0002]\]. Quality of life is considered especially important in long-term breast cancer survivors who were premenopausal at diagnosis \[[@CIT0003]\]. Tumours in this population tend to be more aggressive, and patients are generally offered multi-modal therapies that can be more toxic than individual ones \[[@CIT0004]\]. Their QL may be hampered by factors that are common among survivors, and also by specific problems such as transition to menopause. More research is required into the factors that determine the QL of these patients \[[@CIT0003]\].

To our knowledge, few studies have assessed QL only in young early-stage breast cancer survivors \[[@CIT0005]\] and none has been conducted in Spain. Moreover, most studies performed with breast cancer survivors (with different ages and disease stages) have a follow-up period of less than 10 years. More research is needed into long-term QL in breast cancer patients \[[@CIT0006]\].

Worries about future health are considered one of the main QL dimensions in breast cancer \[[@CIT0007]\]. Fear of recurrence, a key component of future health worries, is a common stress factor reported by breast cancer survivors \[[@CIT0008]\]. Future perspective and overall QL have been compromised in a review of studies performed with premenopausal breast cancer survivors \[[@CIT0003]\]. Few studies have analysed factors related to future perspective or global QL in young early-stage breast cancer survivors more than three years after diagnosis \[[@CIT0009]--[@CIT0011]\], and none of them has been conducted in our cultural area. These studies may allow health professionals to adjust follow-up management and interventions to the patients' needs \[[@CIT0012]\].

Other studies of global QL \[[@CIT0001], [@CIT0012]--[@CIT0020]\] and future perspective determinants \[[@CIT0008], [@CIT0013], [@CIT0018], [@CIT0020]--[@CIT0026]\] have been conducted with breast cancer survivors in early or advanced disease stages and at a variety of ages.

Cross-cultural differences have been found in QL among breast cancer survivors \[[@CIT0027]\]. QL studies conducted in different cultural areas may help to determine the characteristics of breast cancer survivors in each one.

The aims of this study were to assess QL in a sample of premenopausal early-stage breast cancer patients from Spain who are in a long period of follow-up and to evaluate the determinants of two key QL areas: future perspective and global QL. We expected the determinants of these QL areas to be a combination of psychosocial and medical QL dimensions, such as emotional and social functioning, and fatigue. We also expected to find few clinical and demographic variables to be determinants of global QL and future perspective.

Material and methods {#S0002}
====================

Participants {#S20003}
------------

A consecutive sample of stage I--IIIA breast cancer patients treated at a tertiary metropolitan hospital in Spain was recruited (September 2011 -- January 2014). Patients were premenopausal when treated and had undergone surgery 5 to 20 years previously. Premenopausal women were identified as those with menses and those without menses in the last six months but with plasmatic hormonal levels suggesting an active ovarian function. They were disease free, had no relapse or second malignancy, and may have received surgery and various adjuvant treatments. Patients with a second line of treatment or whose cognitive state did not permit QL evaluation were excluded.

Measures {#S20004}
--------

Patients completed the EORTC QLQ-C30 (3.0) \[[@CIT0028]\] and the QLQ-BR23 \[[@CIT0007]\] questionnaires, which had been translated into Spanish \[[@CIT0029]\] and validated for use in Spain \[[@CIT0030], [@CIT0031]\]. The QLQ-C30 comprises 30 items that evaluate areas common to different tumour sites and treatments. It includes five functioning and eight symptoms scales and/or items, a financial impact item, and a global scale. The QLQ-BR23 evaluates areas associated with breast cancer and its treatments. It includes four functioning and four symptoms scales and/or items. Scores in all areas range from 0 to 100. A higher score represents a higher functional level or a higher degree of symptoms. Sociodemographic and clinical data were obtained from clinical records. QL questionnaires with \< 70% of the items answered were excluded.

Data collection procedures {#S20005}
--------------------------

Patients were addressed during one of their outpatient follow-up visits. They were given oral and written information about the research by their treating physician. Patients who provided informed consent completed the questionnaires once after their follow-up visit. This study followed the recommendations of the Declaration of Helsinki and was approved by the Ethics Committee of the Hospital.

Statistical analysis {#S20006}
--------------------

To identify which patients' characteristics were related to bad future perspective and low global QL (dependent variables), univariate logistic regression analyses were performed with the categorised scores as response variables and the sociodemographic, clinical (age at evaluation, age when diagnosed, marital status, breast and axillary surgery modalities, having/not having received chemotherapy, radiotherapy, and/or endocrine therapy, limiting comorbidity, menopause, time since surgery) and QL areas as explanatory (independent) variables (0--33 and 0--50 points were considered low future perspective and low global QL, respectively). Global QL was assessed through two specific QLQ-C30 items that assess overall health and overall QL, and future perspective through a QLQ-BR23 item that assesses worries about future health. Multivariate logistic regression models using the backward regression method and including those areas found to be significant in univariate logistic regression were also performed to complement the analyses. Calibration of the models was checked using the Hosmer & Lemenshow test, and the models were selected using statistical indicators such as the percentage of correct classification, the area under the ROC curve with its 95% CI, and the R^2^ of Nagelkerke.

Results {#S0007}
=======

Out of 259 candidates, 243 patients were evaluated. Reasons for not completing the questionnaires were administrative failure (10 cases) and patient refusal (6 cases). All questionnaires had \> 70% of the items answered. The sociodemographic and clinical characteristics of these patients are shown in [Table 1](#T0001){ref-type="table"}. The mean present age was 54.2 and the mean time since surgery was 9.8 years. Conservative surgery had been performed on 67.5% of the patients.

###### 

Sociodemographic and clinical characteristics of the sample

  -------------------------------------------------------------------------
  Characteristics                          *N*    Percentage   Mean   SD
  ---------------------------------------- ------ ------------ ------ -----
  Present age (range 34--68)                                   54.2   6.8

  Age when diagnosed (range 28--56)                            44.7   5.3

  Time since surgery (range 5--20 years)                       9.8    4.0

  Marital Status\                          \      \                   
   Single\                                 31\    12.8\               
   Married\                                177\   72.8\               
   Widowed\                                12\    4.9\                
   Separated                               23     9.5                 

  Breast Surgery\                          \      \                   
   Conservative\                           164\   67.5\               
   Mastectomy                              79     32.5                

  Axillary Surgery\                        \      \                   
   Lymphadenectomy\                        192\   79.0\               
   Sentinel node                           51     21.0                

  Chemotherapy\                            \      \                   
   Taxanes\                                8\     3.3\                
   Anthracyclines\                         76\    31.3\               
   Taxanes + anthracyclines\               33\    13.6\               
   Other\                                  \      \                   
   No                                      70\    28.8\               
                                           56     23.0                

  Radiotherapy\                            \      \                   
   Yes\                                    190\   78.2\               
   No                                      \      21.8                
                                           40                         

  Endocrine therapy\                       \      \                   
   Tamoxifen\                              147\   60.5\               
   LH-RH analogues\                        4\     1.6\                
   No\                                     70\    28.8\               
   Other\                                  2\     0.9\                
   Tamoxifen + LH-RH analogues             20     8.2                 

  Limiting Comorbidity\                    \      \                   
  \                                        38\    15.6\               
   Yes\                                    205    84.4                
  \                                                                   
   No                                                                 

  Menopause\                               \      \                   
   Yes\                                    206\   84.8\               
   No                                      37     15.2                
  -------------------------------------------------------------------------

LH-RH -- luteinising hormone-releasing hormone

Quality of Life mean scores were high in most areas (\> 80 points in functioning; \< 20 points in symptoms areas; [Table 2](#T0002){ref-type="table"}). Moderate limitations occurred in global QL, sleep disturbance, future perspective, and sexual functioning and enjoyment (affectation \> 30). Light affectation (20 to 29 points) appeared in emotional functioning, fatigue, pain, and systemic therapy side effects.

###### 

Mean scores for QLQ-C30 and QLQ-BR23 areas and association with future perspective and global QL

                                                                  Bad Future Perspective   Low Global QL                                                    
  --------------------------------------------------------------- ------------------------ ------------------- ------ ---------- ------------------- ------ ----------
  Physical[1](#TF0001){ref-type="table-fn"}                       88.2 (15.1)              0.95 (0.93--0.97)   0.16   \< 0.001   0.92 (0.89--0.94)   0.31   \< 0.001
  Role[1](#TF0001){ref-type="table-fn"}                           86.5 (24.5)              0.96 (0.94--0.97)   0.25   \< 0.001   0.96 (0.95--0.98)   0.23   \< 0.001
  Emotional[1](#TF0001){ref-type="table-fn"}                      76.7 (25.6)              0.93 (0.91--0.95)   0.52   \< 0.001   0.96 (0.94--0.97)   0.27   \< 0.001
  Cognitive[1](#TF0001){ref-type="table-fn"}                      85.1 (22.1)              0.96 (0.95--0.98)   0.20   \< 0.001   0.96 (0.95--0.97)   0.20   \< 0.001
  Social[1](#TF0001){ref-type="table-fn"}                         86.8 (24.7)              0.96 (0.95--0.97)   0.26   \< 0.001   0.96 (0.94--0.97)   0.27   \< 0.001
  Global[1](#TF0001){ref-type="table-fn"}                         70.9 (23.9)              0.95 (0.94--0.97)   0.29   \< 0.001                       --     --
  Fatigue[2](#TF0002){ref-type="table-fn"}                        21.1 (24.4)              1.05 (1.03--1.06)   0.30   \< 0.001   1.07 (1.05--1.09)   0.47   \< 0.001
  Nausea[2](#TF0002){ref-type="table-fn"}                         3.5 (12.1)               1.09 (1.05--1.24)   0.19   \< 0.001   1.07 (1.03--1.10)   0.12   \< 0.001
  Pain[2](#TF0002){ref-type="table-fn"}                           20.2 (26.1)              1.04 (1.02--1.05)   0.25   \< 0.001   1.05 (1.03--1.06)   0.31   \< 0.001
  Dyspnoea[2](#TF0002){ref-type="table-fn"}                       6.2 (17.4)               1.04 (1.02--1.06)   0.12   \< 0.001   1.04 (1.02--1.06)   0.14   \< 0.001
  Sleep disturbance[2](#TF0002){ref-type="table-fn"}              31.3 (32.6)              1.03 (1.02--1.04)   0.20   \< 0.001   1.02 (1.01--1.04)   0.15   \< 0.001
  Appetite loss[2](#TF0002){ref-type="table-fn"}                  7.5 (18.2)               1.04 (1.02--1.05)   0.12   \< 0.001   1.02 (1.01--1.04)   0.05   0.003
  Constipation[2](#TF0002){ref-type="table-fn"}                   17.9 (29.2)              1.01 (0.99--1.02)   0.02   0.117      1.01 (1.00--1.02)   0.02   0.038
  Diarrhoea[2](#TF0002){ref-type="table-fn"}                      4.8 (15.3)               1.02 (1.01--1.04)   0.04   0.012      1.02 (1.00--1.04)   0.02   0.053
  Financial impact[2](#TF0002){ref-type="table-fn"}               12.9 (29.3)              1.03 (1.02--1.04)   0.15   \< 0.001   1.02 (1.01--1.03)   0.12   \< 0.001
  **QLQ-BR23 AREAS**                                                                                                                                        
  Body image[1](#TF0001){ref-type="table-fn"}                     82.2 (29.3)              0.96 (0.95--0.98)   0.27   \< 0.001   0.97 (0.96--0.99)   0.15   \< 0.001
  Sexual functioning[1](#TF0001){ref-type="table-fn"}             27.3 (24.3)              0.98 (0.96--0.99)   0.07   0.002      0.98 (0.96--0.99)   0.07   \< 0.001
  Sexual enjoyment[1](#TF0001){ref-type="table-fn"}               50.4 (31.0)              0.99 (0.98--1.01)   0.01   0.477      0.98 (0.97--0.99)   0.04   0.042
  Future perspective[1](#TF0001){ref-type="table-fn"}             65.2 (33.8)                                         --         0.97 (0.96--0.98)   0.22   \< 0.001
  Arm symptoms[2](#TF0002){ref-type="table-fn"}                   18.9 (23.2)              1.04 (1.03--1.06)   0.23   \< 0.001   1.04 (1.02--1.05)   0.20   \< 0.001
  Breast symptoms[2](#TF0002){ref-type="table-fn"}                14.8 (18.2)              1.06 (1.04--1.09)   0.29   \< 0.001   1.04 (1.03--1.06)   0.16   \< 0.001
  Systemic therapy side effect[2](#TF0002){ref-type="table-fn"}   20.0 (19.1)              1.06 (1.04--1.08)   0.27   \< 0.001   1.06 (1.04--1.08)   0.25   \< 0.001
  Upset by hair loss[2](#TF0002){ref-type="table-fn"}             20.8 (32.2)              1.02 (1.01--1.03)   0.11   0.006      1.02 (1.01--1.03)   0.10   0.008

Functioning areas and global QL. The scores range from 0 to 100, where a higher score represents a higher functional level

Symptoms areas and financial impact. The scores range from 0 to 100, where a higher score represents a greater degree of symptoms

Future perspective {#S20008}
------------------

Mean future perspective was 65.2. No significant relationship was found between future perspective and any of the clinical and demographic variables in the univariate logistic regression analyses. The QL areas with the highest R^2^ were emotional and social functioning, body image (higher values were associated with better future perspective), fatigue, arm symptoms, breast symptoms, and systemic therapy side effects (higher values were associated with lower future perspective) ([Table 3](#T0003){ref-type="table"}).

###### 

Multivariate analyses: predictive factors of future perspective and global QL

                                                     Estimates                      
  -------------------------------------------------- ------------------- ---------- -----
  **Model 1: Risk to Low Future Perspective**                                       56%
  Emotional[1](#TF0003){ref-type="table-fn"}         0.94 (0.93--0.96)   \< 0.001   
  Social[1](#TF0003){ref-type="table-fn"}            0.98 (0.97--1.00)   0.068      
  Breast symptoms[2](#TF0004){ref-type="table-fn"}   1.03 (1.01--1.06)   0.025      
  **Model 2: Risk to Low Global QL**                                                50%
  Physical[1](#TF0003){ref-type="table-fn"}          0.97 (0.94--1.01)   0.135      
  Emotional[1](#TF0003){ref-type="table-fn"}         0.98 (0.97--1.00)   0.121      
  Fatigue[2](#TF0004){ref-type="table-fn"}           1.06 (1.03--1.08)   \< 0.001   

The scores range from 0 to 100, where a higher score represents a higher functional level

The scores range from 0 to 100, where a higher score represents a greater degree of symptoms

The best logistic model to explain future perspective in the multivariate logistic regression analyses identified high emotional and social functioning and low breast symptoms (radiotherapy side effects) as variables associated with lower risk of low future perspective: R^2^ = 0.56; ROC = 0.91 (95% CI: 0.86--0.95), and % of correct classification = 88%. Calibration of the model: $\chi_{7}^{2}$ = 5.25 (*p* = 0.629) (see [Table 3](#T0003){ref-type="table"}).

Global QL {#S20009}
---------

Mean global QL was 70.9. A significant relationship was found between the risk of low global QL and comorbidity (OR = 3.96, 95% CI: 1.84--8.52, R^2^ = 0.08) in the univariate logistic regression analyses. No other significant relationship was found between global QL and any of the clinical or demographic variables.

The QL areas with the highest R^2^ were physical, emotional, and social functioning (higher values were associated with higher global QL), and fatigue, pain, and systemic therapy side effects (higher values were associated with lower global QL; see [Table 3](#T0003){ref-type="table"}).

The best logistic model to explain global QL in the multivariate logistic regression analyses showed that higher scores in physical and emotional functioning and lower scores in fatigue were associated with a lower risk of low global QL: R^2^ = 0.50; ROC = 0.89 (95% CI: 0.84--0.93), and % of correct classification = 83%. Calibration of the model: $\chi_{8}^{2}$ = 12.36 (*p* = 0.136) (see [Table 3](#T0003){ref-type="table"}).

Discussion {#S0010}
==========

The main results of this study are: QL mean scores in a sample of Spanish long-term premenopausal breast cancer survivors were high in most areas; the main QL factors related to future perspective were emotional and social functioning, fatigue, arm symptoms, breast symptoms, body image, and systemic therapy side effects; the main QL factors related to global QL were fatigue, pain, physical, emotional and social functioning, and systemic therapy side effects; two logistic models to identify which QL areas were most related with future perspective and global QL were fitted. Most clinical and biographical factors were not found to be determinants of future perspective or global QL.

QL scores were generally satisfactory. Our scores are similar to those found in other studies of early-stage breast cancer survivors with a shorter follow-up period that focused on premenopausal patients \[[@CIT0005]\] or those with a wider age range \[[@CIT0001], [@CIT0024]\] and in which the EORTC instruments were administered. These scores are also in line with the EORTC reference values for the QLQ-C30 (general population) \[[@CIT0032]\].

Future perspective limitations were moderate. This result is important if we take into account the fact that patients were at initial disease stages, had a good prognosis, and were in a long follow-up period, all of which may be expected to improve their perspective. These future perspective scores are in line with those from other studies of early-stage breast cancer survivors (though with a wider age range and a shorter follow-up) \[[@CIT0008]\].

Our results on QL determinants of global QL and future perspective are in line with those of other studies (with shorter follow-ups than ours) of young early-stage breast cancer survivors. These studies found emotional functioning to be an explanatory factor of future perspective \[[@CIT0011]\] and physical and emotional functioning and body image (in our case with a lower R^2^) to be global QL explanatory factors \[[@CIT0009], [@CIT0010]\]. Like our study, another study of early-stage breast cancer patients at a variety of ages did not find body image to be a key determinant of global QL \[[@CIT0019]\]. Our results are also in line with those of other studies of QL determinants of global QL \[[@CIT0001], [@CIT0012], [@CIT0015], [@CIT0016], [@CIT0018], [@CIT0019]\] and future perspective \[[@CIT0008], [@CIT0021], [@CIT0023], [@CIT0025], [@CIT0026]\] conducted with breast cancer survivors (at early or advanced disease stages and a variety of ages, and a shorter follow-up period), which showed QL functioning and symptoms areas to be explanatory factors.

We found fatigue and social functioning to be key determinants of both future perspective and global QL. Fatigue has been considered a strong predictor of QL in breast cancer survivors \[[@CIT0002], [@CIT0033]\]. The QLQ-C30 social functioning scale assesses family life and social activities, which are considered key to supporting breast cancer survivors \[[@CIT0001], [@CIT0034]\]. This family and social support role is especially important in Spain \[[@CIT0035]\].

We found a relationship between future perspective (which assesses worries about future health) and the arm symptoms scale, but not with the type of surgery administered. Liu *et al*. \[[@CIT0008]\] found that surgical side effects (including arm symptoms) in early-stage breast cancer survivors (\> 40 years old) were related to fear of recurrence (a key component of worries about future health) and considered the literature to be inconsistent regarding the impact of the type of surgery on fear of recurrence.

Our results on the clinical and demographic determinants of global QL and future perspective are in line with those of other studies of young early-stage breast cancer survivors (with shorter follow-ups than ours). Co-morbidity has been found to be a determinant of global QL \[[@CIT0010]\], whereas age, adjuvant treatments, and, as we have already mentioned, type of surgery have not \[[@CIT0009], [@CIT0010]\]. Unlike us, Thewes *et al*. \[[@CIT0011]\] found a relation between time since diagnosis and fear of recurrence. However, the fact that their study could include young early-stage patients with a shorter follow-up period (one year) may have influenced their results.

Other studies of early stage patients at a variety of ages found no relation between time since diagnosis and global QL or future perspective \[[@CIT0014], [@CIT0023], [@CIT0024]\].

Co-morbidity has also been related to global QL in early-stage breast cancer survivors (at a variety of ages and with a shorter follow-up period) \[[@CIT0016], [@CIT0017]\]. Marital status has not been found to be a determinant of global QL or future perspective in studies of patients at early or a variety of stages and at a variety of ages (and with a shorter follow-up period) \[[@CIT0008], [@CIT0023]\].

Age has been found to be a determinant of global and future perspective in several studies conducted with breast cancer survivors at initial and advanced stages \[[@CIT0002], [@CIT0008], [@CIT0013], [@CIT0014], [@CIT0016], [@CIT0020], [@CIT0025], [@CIT0026]\]. However, these results may have been influenced by the fact that the patients in all of these studies had a broader age range than ours. In other studies of patients at a variety of ages and initial disease stages, age was also not found to be a determinant of global QL or future perspective \[[@CIT0013], [@CIT0020]\]. In some studies, but not in others, adjuvant treatments and surgery modality have been shown to be determinants of global QL or future perspective in patients at early and advanced disease stages and at a variety of ages \[[@CIT0008], [@CIT0013], [@CIT0014], [@CIT0020], [@CIT0023], [@CIT0025], [@CIT0026]\]. In all of the above studies, the follow-up period was shorter than in ours.

Areas measured by the QL questionnaires such as symptoms, side effects, and body image may be related to future perspective (worries about future health) because they could be reminders of the disease. It would be useful to study the level of knowledge women have of their cancer and whether they have a false interpretation of their symptoms and side effects as an indication of a possible negative evolution of their disease \[[@CIT0036]\]. The presence of these chronic symptoms and side effects as possible reminders of the disease may also help to understand the lack of relationship between future perspective and time of follow-up: patients with no relapse and a longer follow-up period may be expected to have a better future perspective since they may believe their disease to be under control.

Some of the key points of this study are the patients' ages, the cultural area, and the long follow-up period. On the other hand, the study could have benefited from a longitudinal design in which QL was measured before treatment as well as during follow-up, in order to identify risk and the protective factors of QL more accurately.

In conclusion, psychological, social, and physical factors have been found to be possible determinants of future perspective and global QL in premenopausal long-term early-stage breast cancer survivors from Spain. These patients could benefit from a multidisciplinary treatment that could help to improve their QL.
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